Eve Rittenberg, Roy Perlis, Sharon Inouye

In this issue of JAMA Internal Medicine, Bressman et al1 propose a clever thought experiment: what if medical tools incorporating artificial intelligence (AI) were licensed as advanced practitioners, rather than solely regulated by the US Food and Drug Administration (FDA)?